Gapping down
In reaction to disappointing earnings/guidance: GME -6.7%
Other news: APRI -57% (reports top-line Phase 2b Data for Fispemifene with secondary hypogonadism; failed to achieve statistical significance in key clinical benefit endpoints), NBL -4.1% (notified that the Supreme Court of the State of Israel affirmed the Government of Israel's Natural Gas Regulatory Framework), SRPT -1.1% (confirms that it has received a notice of nomination from Viex Capita regarding its intention to nominate five directors to its Board)
Analyst comments: ATW -3% (downgraded to Underweight from Equal Weight at Barclays), ESV -2.8% (downgraded to Underweight from Equal Weight at Barclays), PSG -2.4% (downgraded to Underperform from Neutral at BofA/Merrill), QCOM -0.7% (downgraded to Equal Weight from Overweight at Barclays )
In reaction to disappointing earnings/guidance: GME -6.7%
Other news: APRI -57% (reports top-line Phase 2b Data for Fispemifene with secondary hypogonadism; failed to achieve statistical significance in key clinical benefit endpoints), NBL -4.1% (notified that the Supreme Court of the State of Israel affirmed the Government of Israel's Natural Gas Regulatory Framework), SRPT -1.1% (confirms that it has received a notice of nomination from Viex Capita regarding its intention to nominate five directors to its Board)
Analyst comments: ATW -3% (downgraded to Underweight from Equal Weight at Barclays), ESV -2.8% (downgraded to Underweight from Equal Weight at Barclays), PSG -2.4% (downgraded to Underperform from Neutral at BofA/Merrill), QCOM -0.7% (downgraded to Equal Weight from Overweight at Barclays )